GlobeNewswire Inc | Nov 8, 2021 04:05PM EST

November 08, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced thatArnon Rosenthal, Ph.D., Chief Executive Officer of Alector, will participate in a fireside chat at theStifel2021Virtual Healthcare ConferenceonMonday, November 15, 2021, at2:00 p.m. ET.

A live webcast of the fireside chat will be available on the Events & Presentations page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.

AboutAlector

Alectoris a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases.Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alectors immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease. This scientific approach is also the basis for the companys immuno-oncology programs. Alector is headquartered inSouth San Francisco, California. For additional information, please visitwww.alector.com.

Contacts

1ABDan Budwick973-271-6085dan@1abmedia.com

or

Investors:Alector, Inc.ir@alector.com